Lancet Haematology

Lancet Haematology

柳叶刀血液学

  • 1区 中科院分区
  • Q1 JCR分区

期刊简介

《Lancet Haematology》是由Lancet Publishing Group出版社于2014年创办的英文国际期刊(ISSN: 2352-3026),该期刊长期致力于血液学领域的创新研究,主要研究方向为HEMATOLOGY。作为SCI、SCIE收录期刊(JCR分区 Q1,中科院 1区),本刊采用OA未开放获取模式(OA占比0.0796...%),以发表血液学领域等方向的原创性研究为核心(研究类文章占比82.61%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在69篇,确保学术质量与前沿性。成果覆盖Web of ScienceWeb of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Lancet Haematology该刊近年未被列入国际预警名单,年发文量约69篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCI、SCIE 期刊收录
  • 69 发文量

中科院分区

《新锐期刊分区表》(2026年3月发布)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
HEMATOLOGY 血液学
1区

期刊分区表(2025年3月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
HEMATOLOGY 血液学
1区

期刊分区表(2023年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
HEMATOLOGY 血液学
1区

期刊分区表(2022年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
HEMATOLOGY 血液学
1区

期刊分区表(2021年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
1区
HEMATOLOGY 血液学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 3 / 103

97.6

学科:HEMATOLOGY SCIE Q1 2 / 103

98.54

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 4 / 97

96.4

学科:HEMATOLOGY SCIE Q1 3 / 97

97.42

CiteScore(2026年6月最新版)

CiteScore SJR SNIP CiteScore 排名
CiteScore:29.4 SJR:6.899 SNIP:5.497
学科类别 分区 排名 百分位
大类:Medicine 小类:Hematology Q1 5 / 151

97%

期刊发文

  • Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VT

    Author: Cheng, Zhang; Jin, Yiqi

    Journal: LANCET HAEMATOLOGY. 2026; Vol. 13, Issue 3, pp. e124-e124. DOI:

  • Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 tria

    Author: Wang, Xin-Yue; Zhang, Xi-Mei; Wang, Liang; Gao, Lin-Rui; Chen, Ke; Feng, Xiao-Li; Rao, Wei; Zheng, Rong; Wu, Yun-Peng; Song, Yong-Wen; Fang, Hui; Chen, Bo; Jin, Jing; Liu, Yue-Ping; Jing, Hao; Tang, Yuan; Zhang, Wen-Wen; Zhai, Yi-Rui; Lu, Ning-Ning; Li, Ning; Xia, Chang-Fa; Wang, Shu-Lian; Liu, Xin; Li, Ye-Xiong; Qi, Shu-Nan

    Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e442-e450. DOI: 10.1016/S2352-3026(25)00071-7

  • Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitor

    Author: Risitano, Antonio M.; Kulasekararaj, Austin G.; Scheinberg, Phillip; Roeth, Alexander; Han, Bing; Maciejewski, Jaroslaw P.; Ueda, Yasutaka; de Castro, Carlos M.; Di Bona, Eros; Fu, Rong; Zhang, Li; Griffin, Morag; Langemeijer, Saskia M. C.; Panse, Jens; Schrezenmeier, Hubert; Barcellini, Wilma; Mauad, Vitor A. Q.; Schafhausen, Philippe; Tavitian, Suzanne; Beggiato, Eloise; Chew, Lee Ping; Gaya, Anna; Huang, Wei-Han; Hojang, Jun; Kitawaki, Toshio; Kutlar, Abdullah; Notaro, Rosario; Pullarkat, Vinod; Schubert, Joerg; Terriou, Louis; Uchiyama, Michihiro; Lee, Lily Wong Lee; Yap, Eng-Soo; Frieri, Camilla; Marano, Luana; de Fontbrune, Flore Sicre; Gandhi, Shreyans; Trikha, Roochi; Alashkar, Ferras; Yang, Chen; Liu, Hui; Kelly, Richard J.; Hoechsmann, Britta; Lawniczek, Tomasz; Mahajan, Navin; Solar-Yohay, Susan; Kerloeguen, Cecile; Ferber, Philippe; Kumar, Rakesh; Wang, Zhixin; Thorburn, Christine; Maitra, Samopriyo; Li, Shujie; Verles, Aurelie; Dahlke, Marion; de Latour, Regis Peffault

    Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e414-e430. DOI:

  • Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancie

    Author: Broeckelmann, Paul J.; Cliff, Edward R. Scheffer; Iacoboni, Gloria; Simon, Florian; Horowitz, Mary M.; Keating, Armand; Mateos, Maria-Victoria; Mohty, Mohamad; Sidana, Surbhi; Song, Yuqin; Wingard, John R.; Thanarajasingam, Gita

    Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 6, pp. e470-e481. DOI: 10.1016/S2352-3026(25)00051-1

  • Anti-GPRC5D CART-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CART-cell therapy: a single-centre, single-arm, phase 2 tria

    Author: Xia, Jieyun; Sun, Qian; Zhou, Dian; Li, Hujun; Wang, Ying; Qi, Yuekun; Cao, Jiang; Yan, Zhiling; Li, Depeng; Cheng, Hai; Sang, Wei; Zhu, Feng; Sun, Haiying; Chen, Wei; Qi, Kunming; Yan, Dongmei; Qiu, Tingting; Hu, Tingyu; Gu, Weiying; Qian, Jun; Xia, Fan; Qi, Na; Jin, Congqian; Liu, Yang; Wang, Xue; Zhang, Yanlei; Peng, Shuixiu; Li, Zhenyu; Chang, Alex H.; Xu, Kailin

    Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 5, pp. e365-e375. DOI: 10.1016/S2352-3026(25)00048-1

  • Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 stud

    Author: Zhao, Xin; Sun, Jing; Zhang, Zhihua; Chen, Miao; Gong, Tiejun; He, Guangsheng; Li, Yingmei; Liu, Hong; Li, Fei; Li, Xin; Zhou, Hu; Wang, Xiaoqin; Hong, Mei; Lei, Lei; Yin, Hongyan; Luo, Xian; Li, Yang; Fan, Songhua; Guo, Xiaojun; Shi, Michael M.; Su, Weiguo; Zhang, Liansheng; Han, Bing; Zhang, Fengkui

    Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 2, pp. e97-e108. DOI: 10.1016/S2352-3026(24)00344-2

  • Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre single-arm, phase 2 tria

    Author: Alderuccio, Juan Pablo; Alencar, Alvaro J.; Schatz, Jonathan H.; Kuker, Russ A.; Pongas, Georgios; Reis, Isildinha M.; Lekakis, Lazaros J.; Spiegel, Jay Y.; Sandoval-Sus, Jose; Beitinjaneh, Amer; Stanchina, Michele D.; Trabolsi, Asaad; Lossos, Izidore S.; Rosenblatt, Joseph D.; Lessen, David S.; Moskowitz, Craig H.

    Journal: LANCET HAEMATOLOGY. 2025; Vol. 12, Issue 1, pp. e23-e34. DOI: 10.1016/S2352-3026(24)00345-4